Key Findings:  In this study of moderately active Crohn's disease, CBD was safe but had no beneficial effects. This could be due to lack of effect of CBD on Crohn's disease, but could also be due to the small dose of CBD, the small number of patients in the study, or the lack of the necessary synergism with other cannabinoids. Further investigation is warranted.
Type of Study:  Double Blind Clinical Trial
Study Sample Size:  20
Study Result:  Inconclusive
Study Location(s):  Israel
Year of Pub:  2017
Cannabinoids Studied:  Cannabidiol (CBD)
Phytocannabinoid Source:  Unspecified
Chemotype:  Chemotype III
Sub-Ratio: 0:1 (THC:CBD)
Dosage: CBD (10 mg) or placebo 2x daily.
Route of Administration:  Oral (Ingestion)